Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer
Open accessAbstract
Immunotherapy has become a standard treatment in many cancers and it is based on three main therapeutic axes: immune checkpoint blockade (ICB), vaccination and adoptive cell transfer (ACT). If originally these therapies mainly focused on exploiting CD8 T cells given their role in the direct elimination of tumor cells, increasing evidence highlights the crucial role CD4 T cells play in the antitumor immune response. Indeed, these cells can profoundly modulate the tumor microenvironment (TME) by secreting different types of cytokine or by directly eliminating cancer cells. In this review, we describe how different CD4 T cell subsets can contribute to tumor immune responses during immunotherapy and the novel high-throughput immune monitoring tools that are expected to facilitate the study of CD4 T cells, at antigen-specific and single cell level, thus accelerating bench-to-bed translational research in cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CD4+ Th1 cells contribute to the anti-tumoral response by secreting pro-inflammatory cytokines such as IL-2, TNF-α, and IFN-γ.
“Simultaneously, CD4+ Th1 cells contribute to the anti-tumoral response by secreting pro-inflammatory cytokines such as IL-2, TNF-α, and IFN-γ [1,10].”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,244 · see citing works
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · see citing works
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · see citing works
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936 · see citing works
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · see citing works
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · see citing works
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263 · see citing works
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,145 · see citing works
Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells
Acosta-Rodriguez, E. V., Rivino, L., Geginat, J., Jarrossay, D., Gattorno, M., Lanzavecchia, A., Sallusto, F., & Napolitani, G. (2007) · Nature Immunology · doi:10.1038/ni1467 · Cited by 1,828 · see citing works
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,710 · see citing works
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647 · see citing works
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · see citing works
Dendritic cells in a mature age
Sousa, C. R. E. (2006) · Nature reviews. Immunology · doi:10.1038/nri1845 · Cited by 1,197 · see citing works
Melief, C. J. M., van Hall, T., Arens, R., OSSENDORP, F. A., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,182 · see citing works
Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S., Jones, L. A., & Hershberg, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5252 · Cited by 1,108 · see citing works
Dendritic cell regulation of TH1-TH2 development
Moser, M., & MURPHY, K. M. M. (2000) · Nature Immunology · doi:10.1038/79734 · Cited by 1,106 · see citing works
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Löwik, M. J. G., der Meer, D. M. A. B.-V., Vloon, A. P. G., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810097 · Cited by 1,101 · see citing works
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2537-9 · Cited by 1,052 · see citing works
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Kamada, T., Togashi, Y., Tay, C., Ha, D., Sasaki, A., Nakamura, Y., Sato, E., Fukuoka, S., Tada, Y., Tanaka, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822001116 · Cited by 1,006 · see citing works
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963 · see citing works
Dendritic cell immunotherapy: mapping the way
Figdor, C. G., de Vries, I. J. M., Lesterhuis, W. J., & Melief, C. J. M. (2004) · Nature Medicine · doi:10.1038/nm1039 · Cited by 940 · see citing works
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 915 · see citing works
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N. H., Wallen, H. D., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R. M., Jungbluth, A. A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 904 · see citing works
Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P. A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091918 · Cited by 898 · see citing works
Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Tay, R. E., Richardson, E. K., & Toh, H. C. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 801 · see citing works
Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.053 · Cited by 738 · see citing works
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
Oh, D. Y., Kwek, S. S., Raju, S. S., Li, T., McCarthy, E., Chow, E., Aran, D., Ilano, A., Pai, C.-C. S., Rancan, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.017 · Cited by 734 · see citing works
Trimble, C. L., Morrow, M. P., Kraynyak, K. A., Shen, X., Dallas, M. J., Yan, J., Edwards, L., Parker, R. L., Denny, L., Giffear, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00239-1 · Cited by 732 · see citing works
Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 671 · see citing works
Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., Ezoe, S., Kanakura, Y., Sato, E., Fukumori, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316796110 · Cited by 629 · see citing works
Stability of Endogenous and Added RNA in Blood Specimens, Serum, and Plasma
Tsui, N. B. Y., Ng, E. K. O., & Lo, Y. D. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.10.1647 · Cited by 628 · see citing works
cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity
Ferris, S. T., Durai, V., Wu, R., Theisen, D. J., Ward, J. P., Bern, M. D., Davidson, J. T., Bagadia, P., Liu, T., Briseño, C. G., et al. (2020) · Nature · doi:10.1038/s41586-020-2611-3 · Cited by 611 · see citing works
Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417320112 · Cited by 601 · see citing works
Self-citationFc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592 · see citing works
The urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585 · see citing works
Hu, Z., Leet, D., Allesøe, R. L., Oliveira, G., Li, S., Luoma, A., Liu, J., Forman, J., Huang, T., Iorgulescu, J. B., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01206-4 · Cited by 550 · see citing works
Vansteenkiste, J., Cho, B. C., Vanakesa, T., Pas, T. M. D., Zielinski, M., Kim, M. S., Jassem, J., Yoshimura, M., Dahabreh, J., Nakayama, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00099-1 · Cited by 512 · see citing works
VISTA is an immune checkpoint molecule for human T cells
Lines, J. L., Pantazi, E., Mak, J., Sempere, L. F., Wang, L., O'Connell, S., Ceeraz, S., Suriawinata, A. A., Yan, S., Ernstoff, M. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1504 · Cited by 510 · see citing works
Engineering dendritic cell vaccines to improve cancer immunotherapy
Perez, C. R., & Palma, M. D. (2019) · Nature Communications · doi:10.1038/s41467-019-13368-y · Cited by 507 · see citing works
Czerkinsky, C. C., Andersson, G., Ekre, H.-P. T., Nilsson, L., Klareskog, L., & Ouchterlony, Ö. (1988) · Journal of Immunological Methods · doi:10.1016/0022-1759(88)90079-8 · Cited by 495 · see citing works
Direct access to CD4+ T cells specific for defined antigens according to CD154 expression
Frentsch, M., Arbach, O., Kirchhoff, D., Moewes, B., Worm, M., Rothe, M., Scheffold, A., & Thiel, A. (2005) · Nature Medicine · doi:10.1038/nm1292 · Cited by 475 · see citing works
LAG-3: from molecular functions to clinical applications
Maruhashi, T., Sugiura, D., Okazaki, I., & Okazaki, T. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001014 · Cited by 462 · see citing works
Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma
Xie, Y., Akpınarlı, A., Maris, C. H., Hipkiss, E. L., Lane, M. V., Kwon, E. M., Muranski, P. J., Restifo, N. P., & Antony, P. A. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20091921 · Cited by 455 · see citing works
Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells
Purwar, R., Schlapbach, C., Xiao, S., Kang, H. S., Elyaman, W., Jiang, X., Jetten, A. M., Khoury, S. J., Fuhlbrigge, R. C., Kuchroo, V. K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2856 · Cited by 442 · see citing works
CD4 cells can be more efficient at tumor rejection than CD8 cells
Pérez‐Díez, A., Joncker, N. T., Choi, K., Chan, W. F. N., Anderson, C. C., Lantz, O. J., & Matzinger, P. (2007) · Blood · doi:10.1182/blood-2006-10-051318 · Cited by 436 · see citing works
mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer
Cafri, G., Gartner, J. J., Zaks, T., Hopson, K., Levin, N., Paria, B. C., Parkhurst, M. R., Yossef, R., Lowery, F. J., Jafferji, M. S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134915 · Cited by 427 · see citing works
mRNA vaccine: a potential therapeutic strategy
Wang, Y., Zhang, Z., Luo, J., Han, X., Wei, Y., & Wei, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01311-z · Cited by 422 · see citing works
Shah, N. N., Highfill, S. L., Shalabi, H., Yates, B., Jin, J., Wolters, P. L., Ombrello, A., Steinberg, S. M., Martin, S., Delbrook, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03279 · Cited by 421 · see citing works
Zwaveling, S., Mota, S. C. F., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., van der Burg, S. H., & Melief, C. J. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.350 · Cited by 416 · see citing works
Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems
Guan, S., & Rosenecker, J. (2017) · Gene Therapy · doi:10.1038/gt.2017.5 · Cited by 389 · see citing works
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0762 · Cited by 382 · see citing works
Single-cell technologies for monitoring immune systems
Chattopadhyay, P. K., Gierahn, T. M., Roederer, M., & Love, J. C. (2014) · Nature Immunology · doi:10.1038/ni.2796 · Cited by 368 · see citing works
CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer
Gu-Trantien, C., Migliori, E., Buisseret, L., de Wind, A., Brohée, S., Garaud, S., Noël, G., Dang Chi, V. L., Lodewyckx, J.-N., Naveaux, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91487 · Cited by 368 · see citing works
Th9 cells promote antitumor immune responses in vivo
Lu, Y., Hong, S., Li, H., Park, J., Hong, B., Wang, L., Zheng, Y., Liu, Z., Xu, J., He, J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65459 · Cited by 361 · see citing works
Tel, J., Aarntzen, E. H. J. G., Baba, T., Schreibelt, G., Schulte, B. M., Benítez‐Ribas, D., Boerman, O. C., Croockewit, S., Oyen, W. J. G., van Rossum, M. M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2583 · Cited by 351 · see citing works
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer
Cachot, A., Bilous, M., Liu, Y., Li, X., Saillard, M., Cenerenti, M., Rockinger, G. A., Wyss, T., Guillaume, P., Schmidt, J., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe3348 · Cited by 327 · see citing works
Self-citationSharma, A., Subudhi, S. K., Blando, J. M., Vence, L. M., Wargo, J. A., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 314 · see citing works
Hadrup, S. R., Bakker, A. H., Shu, C. J., Andersen, R. S., van Veluw, J., Hombrink, P., Castermans, E., thor Straten, P., Blank, C., Haanen, J. B., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1345 · Cited by 306 · see citing works
Weiskopf, D., Bangs, D. J., Sidney, J., Kolla, R. V., Silva, A. D. D., de Silva, A. M., Crotty, S., Peters, B., & Sette, A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505956112 · Cited by 303 · see citing works
Gunn, G. R., Zubair, A. C., Peters, C., Pan, Z.-K., Wu, T.-C., & Paterson, Y. Y. W. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6471 · Cited by 298 · see citing works
Lu, Y., Parker, L. L., Lu, T., Zheng, Z., Toomey, M. A., White, D. E., Yao, X., Li, Y. F., Robbins, P. F., Feldman, S. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5463 · Cited by 278 · see citing works
Sabbatini, P. J., Tsuji, T., Ferran, L. J., Ritter, E., Sedrak, C., Tuballes, K., Jungbluth, A. A., Ritter, G., Aghajanian, C. A., Bell‐McGuinn, K. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2189 · Cited by 272 · see citing works
Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity
Wang, D., Aguilar, B., Starr, R., Alizadeh, D., Brito, A., Sarkissian, A., Ostberg, J. R., Forman, S. J., & Brown, C. E. (2018) · JCI Insight · doi:10.1172/jci.insight.99048 · Cited by 233 · see citing works
Śledzińska, A., Vila de Mucha, M., Bergerhoff, K., Hotblack, A., Demane, D. F., Ghorani, E., Akarca, A. U., Marzolini, M. A. V., Solomon, I., Vargas, F. A., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.007 · Cited by 228 · see citing works
Papachristofilou, A., Hipp, M., Klinkhardt, U., Früh, M., Sebastian, M., Weiß, C., Pless, M., Cathomas, R. L., Hilbe, W., Pall, G., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0520-5 · Cited by 228 · see citing works
Rational design of anti-GITR-based combination immunotherapy
Zappasodi, R., Sirard, C. A., Li, Y., Budhu, S., Abu-Akeel, M., Liu, C., Yang, X., Zhong, H., Newman, W., Qi, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0420-8 · Cited by 227 · see citing works
Karlsson, A. C., Martin, J. N., Younger, S. R., Bredt, B. M., Epling, L., Ronquillo, R., Varma, A., Deeks, S. G., McCune, J. M., Nixon, D. F., et al. (2003) · Journal of Immunological Methods · doi:10.1016/j.jim.2003.09.001 · Cited by 224 · see citing works
The paradox of Th17 cell functions in tumor immunity
Asadzadeh, Z., Mohammadi, H., Safarzadeh, E., Hemmatzadeh, M., Mahdian-shakib, A., Jadidi‐Niaragh, F., Azizi, G., & Baradaran, B. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.015 · Cited by 218 · see citing works
Regulatory T cells: a potential target in cancer immunotherapy
Shitara, K., & Nishikawa, H. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13625 · Cited by 215 · see citing works
TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
Yang, Y., Kohler, M. E., Chien, C. D., Sauter, C. T., Jacoby, E., Yan, C., Hu, Y., Wanhainen, K., Qin, H., & Fry, T. J. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1209 · Cited by 208 · see citing works
Geiger, R., Duhen, T., Lanzavecchia, A., & Sallusto, F. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090504 · Cited by 207 · see citing works
Dréno, B., Thompson, J. F., Smithers, B. M., Santinami, M., Jouary, T., Gutzmer, R., Levchenko, E., Rutkowski, P. L., Grob, J., Korovin, S. I., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30254-7 · Cited by 204 · see citing works
Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
Zuazo, M., Arasanz, H., Fernández-Hinojal, G., García-Granda, M. J., Gato, M., Bocanegra, A., Hernández, B., Martínez, M., Teijeira, L., Morilla, I., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910293 · Cited by 197 · see citing works
The Human Vaccines Project: A roadmap for cancer vaccine development
Romero, P. J., Banchereau, J., Bhardwaj, N., Cockett, M. I., Disis, M. L., Dranoff, G., Gilboa, E., Hammond, S. A., Hershberg, R. D., Korman, A. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf0685 · Cited by 194 · see citing works
Self-citationDual role of tumour-infiltrating T helper 17 cells in human colorectal cancer
Amicarella, F., Muraro, M. G., Hirt, C., Cremonesi, E., Padovan, E., Mele, V, Governa, V, Han, J., Huber, X., Droeser, R. A., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310016 · Cited by 189 · see citing works
Profiling lymphocyte interactions at the single-cell level by microfluidic cell pairing
Dura, B., Dougan, S. K., Barisa, M., Hoehl, M. M., Lo, C. T., Ploegh, H. L., & Joel Voldman, B. (2015) · Nature Communications · doi:10.1038/ncomms6940 · Cited by 185 · see citing works
T-cell–based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition
Houot, R., Schultz, L. M., Marabelle, A., & Kohrt, H. E. K. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0190 · Cited by 185 · see citing works
Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients
Atanackovic, D., Altorki, N. K., Stockert, E., Williamson, B., Jungbluth, A. A., Ritter, E., Santiago, D., Ferrara, C. A., Matsuo, M., Selvakumar, A., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3289 · Cited by 184 · see citing works
Basu, P. S., Mehta, A. O., Jain, M. M., Gupta, S., Nagarkar, R. V., John, S., & Petit, R. G. (2018) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001235 · Cited by 183 · see citing works
Simultaneous detection of many T-cell specificities using combinatorial tetramer staining
Newell, E. W., Klein, L. O., Yu, W., & Davis, M. M. (2009) · Nature Methods · doi:10.1038/nmeth.1344 · Cited by 182 · see citing works
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
Bol, K. F., Schreibelt, G., Rabold, K., Wculek, S. K., Schwarze, J. K., Dzionek, A., Teijeira, Á., Kandalaft, L. E., Romero, P. J., Coukos, G., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0580-6 · Cited by 181 · see citing works
Self-citationAarntzen, E. H. J. G., de Vries, I. J. M., Lesterhuis, W. J., Schuurhuis, D. H., Jacobs, J. F. M., Bol, K. F., Schreibelt, G., Mus, R. D. M., de Wilt, J. H. W., Haanen, J. B. A. G., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1127 · Cited by 170 · see citing works
Marchand, M.-C., Punt, C. J. A., Aamdal, S., Escudier, B. J., Kruit, W. H. J., Keilholz, U., Håkansson, L., van Baren, N., Humblet, Y., Mulders, P., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00479-3 · Cited by 169 · see citing works
Keersmaecker, B. D., Claerhout, S., Carrasco, J., Bar, I., Corthals, J., Wilgenhof, S., Neyns, B., & Thielemans, K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000329 · Cited by 168 · see citing works
Plasmonic nanohole array biosensor for label-free and real-time analysis of live cell secretion
Li, X., Soler, M., Özdemir, C. I., Belushkin, A. A., Yesilköy, F., & Altug, H. (2017) · Lab on a Chip · doi:10.1039/c7lc00277g · Cited by 168 · see citing works
Kim, I.-K., Kim, B.-S., Koh, C.-H., Seok, J.-W., Park, J.-S., Shin, K.-S., Bae, E.-A., Lee, G.-E., Jeon, H., Cho, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3922 · Cited by 167 · see citing works
van Poelgeest, M. I. E., Welters, M. J. P., Vermeij, R., Stynenbosch, L. F. M., Loof, N. M., der Meer, D. M. A. B.-V., Löwik, M. J. G., Hamming, I. L. E., van Esch, E. M. G., Hellebrekers, B. W. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2594 · Cited by 167 · see citing works
Sharma, A., Koldovsky, U., Xu, S., Mick, R., Roses, R. E., Fitzpatrick, E., Weinstein, S. P., Nisenbaum, H. L., Levine, B. L., Fox, K. R., et al. (2012) · Cancer · doi:10.1002/cncr.26734 · Cited by 165 · see citing works
Kandalaft, L. E., Powell, D. J., Chiang, C. L.-L., Tanyi, J. L., Kim-Hellmuth, S., Bosch, M. L., Montone, K., Mick, R., Levine, B. L., Torigian, D. A., et al. (2013) · OncoImmunology · doi:10.4161/onci.22664 · Cited by 160 · see citing works
The Role of Antigen Spreading in the Efficacy of Immunotherapies
Brossart, P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0305 · Cited by 157 · see citing works
Duhen, R., Ballesteros‐Merino, C., Frye, A. K., Tran, E., Rajamanickam, V., Chang, S., Koguchi, Y., Bifulco, C. B., Bernard, B. M., Leidner, R. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21383-1 · Cited by 144 · see citing works
Kuball, J. H. E., Schmitz, F., Voss, R.-H., Ferreira, E. A., Engel, R., Guillaume, P., Strand, S., Romero, P. J., Huber, C., Sherman, L. A., et al. (2005) · Immunity · doi:10.1016/j.immuni.2004.12.005 · Cited by 144 · see citing works
Self-citationPD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells
Balança, C.-C., Salvioni, A., Scarlata, C., Michelas, M., Gomez‐Roca, C., Gomez‐Roca, C., Sarradin, V., Tosolini, M., Valle, C., Pont, F., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.142513 · Cited by 144 · see citing works
Fernández-Poma, S. M., Salas‐Benito, D., Lozano, T., Casares, N., Riezu‐Boj, J. I., Mancheño, U., Elizalde, E., Alignani, D., Zubeldia, N., Otano, I., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0236 · Cited by 138 · see citing works
Kitano, S., Tsuji, T., Liu, C., Hirschhorn-Cymerman, D., Kyi, C., Mu, Z., Allison, J. P., Gnjatic, S., Yuan, J. D., & Wolchok, J. D. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0068 · Cited by 134 · see citing works
Bowyer, S. E., Prithviraj, P., Lorigan, P. C., Larkin, J., McArthur, G. A., Atkinson, V. G., Millward, M., Khou, M., Diem, S., Ramanujam, S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.107 · Cited by 129 · see citing works
Nagasaki, J., Togashi, Y., Sugawara, T., Itami, M., Yamauchi, N., Yuda, J., Sugano, M., Ohara, Y., Minami, Y., Nakamae, H., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002098 · Cited by 129 · see citing works
Zhuang, Y., Peng, L., Zhao, Y., Shi, Y., Mao, X., Guo, G., Chen, W., Liu, X., Zhang, J., Liu, T., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1241-5 · Cited by 127 · see citing works
Choi, Y. J., Hur, S. Y., Kim, T. J., Hong, S. R., Lee, J. K., Cho, C., Park, K. S., Woo, J. W., Sung, Y. C., Suh, Y. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1513 · Cited by 120 · see citing works
Koski, G. K., Koldovsky, U., Xu, S., Mick, R., Sharma, A., Fitzpatrick, E., Weinstein, S. P., Nisenbaum, H. L., Levine, B. L., Fox, K. R., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318235f512 · Cited by 114 · see citing works
Feng, Q., Wei, H., Morihara, J. K., Stern, J., Yu, M., Kiviat, N. B., Hellström, I., & Hellström, K. E. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.07.098 · Cited by 108 · see citing works
Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells
Haabeth, O. A. W., Lorvik, K. B., Yagita∥, H., Bogen, B., & Corthay, A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1039763 · Cited by 106 · see citing works
Duftner, C., Goldberger, C., Falkenbach, A., Würzner, R., Falkensammer, B., Pfeiffer, K. P., Märker‐Hermann, E., & Schirmer, M. (2003) · Arthritis Research & Therapy · doi:10.1186/ar793 · Cited by 103 · see citing works
Label‐Free Optofluidic Nanobiosensor Enables Real‐Time Analysis of Single‐Cell Cytokine Secretion
Li, X., Soler, M., Szydzik, C., Khoshmanesh, K., Schmidt, J., Coukos, G., Mitchell, A., & Altug, H. (2018) · Small · doi:10.1002/smll.201800698 · Cited by 102 · see citing works
Atkinson, V. G., Khattak, A., Haydon, A. M., Eastgate, M. A., Roy, A. C., Prithviraj, P., Mueller, C., Brignone, C., & Triebel, F. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001681 · Cited by 101 · see citing works
Laheurte, C., Dosset, M., Vernerey, D., Boullerot, L., Gaugler, B., Gravelin, E., Kaulek, V., Jacquin, M., Cuche, L., Eberst, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0531-5 · Cited by 98 · see citing works
Cytotoxic CD4+ T Cells Drive Multiple Sclerosis Progression
Peeters, L. M., Vanheusden, M., Somers, V. A., Wijmeersch, B. V., Stinissen, P., Broux, B., & Hellings, N. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01160 · Cited by 96 · see citing works
Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy
Stoll, G., Enot, D. P., Mlecnik, B., Galon, J., Zitvogel, L., & Kroemer, G. (2014) · OncoImmunology · doi:10.4161/onci.27884 · Cited by 89 · see citing works
Perret, R., Sierro, S. R., Botelho, N. K., Corgnac, S., Donda, A., & Romero, P. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0875 · Cited by 85 · see citing works
Self-citationZaretsky, I., Polonsky, M., Shifrut, E., Reich-Zeliger, S., Antebi, Y. E., Aidelberg, G., Waysbort, N., & Friedman, N. (2012) · Lab on a Chip · doi:10.1039/c2lc40808b · Cited by 82 · see citing works
Bradshaw, E. M., Kent, S. C., Tripuraneni, V., Orban, T., Ploegh, H. L., Hafler, D. A., & Love, J. C. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.06.009 · Cited by 79 · see citing works
Th9 Cells: A Novel CD4 T-cell Subset in the Immune War against Cancer
Végran, F., Apétoh, L., & Ghiringhelli, F. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2748 · Cited by 77 · see citing works
Torres, A. J., Hill, A. S., & Love, J. C. (2014) · Analytical Chemistry · doi:10.1021/ac4030297 · Cited by 77 · see citing works
McNeel, D. G., Eickhoff, J. C., Johnson, L. E., Roth, A. R., Perk, T., Fong, L. H., Antonarakis, E. S., Wargowski, E., Jeraj, R., & Liu, G. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01701 · Cited by 75 · see citing works
Cytomegalovirus-Specific CD4 T Cells Are Cytolytic and Mediate Vaccine Protection
Verma, S., Weiskopf, D., Gupta, A., McDonald, B., Peters, B., Sette, A., & Benedict, C. A. (2015) · Journal of Virology · doi:10.1128/jvi.02123-15 · Cited by 74 · see citing works
Tosch, C., Bastien, B., Barraud, L., Grellier, B., Nourtier, V., Gantzer, M., Limacher, J. M., Quéméneur, É., Bendjama, K., & Préville, X. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0274-x · Cited by 73 · see citing works
Baumgaertner, P., Nunes, C. C., Cachot, A., Hajjami, H. M.-E., Cagnon, L., Braun, M., Derré, L., Rivals, J. P., Rimoldi, D., Gnjatic, S., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1216290 · Cited by 66 · see citing works
Self-citationLing, A., Lundberg, I. V., Eklöf, V., Wikberg, M. L., Öberg, Å., Edin, S., & Palmqvist, R. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.31 · Cited by 62 · see citing works
Patrinely, J. R., Young, A. C., Quach, H., Williams, G. R., Ye, F., Fan, R., Horn, L., Beckermann, K. E., Gillaspie, E. A., Sosman, J. A., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.05.005 · Cited by 61 · see citing works
Torres, A. J., Contento, R. L., Gordo, S., Wucherpfennig, K. W., & Love, J. C. (2012) · Lab on a Chip · doi:10.1039/c2lc40869d · Cited by 60 · see citing works
Wargowski, E., Johnson, L. E., Eickhoff, J. C., Delmastro, L. E., Staab, M. J., Liu, G., & McNeel, D. G. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0333-y · Cited by 59 · see citing works
Merouane, A., Rey-Villamizar, N., Lu, Y., Liadi, I., Romain, G., Lu, J., Singh, H., Cooper, L. J. N., Varadarajan, N., & Roysam, B. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv355 · Cited by 55 · see citing works
Xie, X., Zhang, J., Zhongyuan, S., Liu, W., Hu, X., Qie, C., Chen, W., Wang, Y., Wang, L. L., Jiang, J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.563044 · Cited by 55 · see citing works
A New VISTA on combination therapy for negative checkpoint regulator blockade
Deng, J., Mercier, I. L., Kuta, A., & Noelle, R. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0190-5 · Cited by 52 · see citing works
Tanyi, J. L., Chiang, C. L.-L., Chiffelle, J., Thierry, A., Baumgartener, P., Huber, F., Goepfert, C., Tarussio, D., Tissot, S., Torigian, D. A., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00297-5 · Cited by 51 · see citing works
Abdul‐Wahid, A., Cydzik, M., Prodeus, A., Alwash, M., Stanojcic, M., Thompson, M., Huang, E. H. ‐., Shively, J. E., Gray‐Owen, S. D., & Gariépy, J. (2016) · International Journal of Cancer · doi:10.1002/ijc.30121 · Cited by 51 · see citing works
Fas signaling-mediated TH9 cell differentiation favors bowel inflammation and antitumor functions
Shen, Y., Song, Z., Lu, X., Ma, Z., Lu, C., Zhang, B., Chen, Y., Duan, M., Apétoh, L., Xu, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10889-4 · Cited by 50 · see citing works
Salomon, N., Vascotto, F., Selmi, A., Vormehr, M., Quinkhardt, J., Bukur, T., Schrörs, B., Löewer, M., Diken, M., Türeci, Ö., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771925 · Cited by 49 · see citing works
Cappuccini, F., Bryant, R. J., Pollock, E., Carter, L. M., Verrill, C. L., Hollidge, J., Poulton, I. D., Baker, M., Mitton, C. H., Baines, A. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000928 · Cited by 49 · see citing works
Self-citationTargeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?
Altomonte, M., Fonsatti, E., Visintin, A., & Maio, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206960 · Cited by 48 · see citing works
Jandus, C., Bioley, G., Dojcinovic, D., Derré, L., Baitsch, L., Wieckowski, S., Rufer, N., Kwok, W. W., Tiercy, J., Luescher, I. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2226 · Cited by 45 · see citing works
Self-citationT-bet promotes potent antitumor activity of CD4+ CAR T cells
Gacerez, A. T., & Sentman, C. L. (2018) · Cancer Gene Therapy · doi:10.1038/s41417-018-0012-7 · Cited by 41 · see citing works
Zhang, Y., Renkvist, N., Sun, Z., Schuler‐Thurner, B., Glaichenhaus, N., Schuler, G., Boon, T., van der Bruggen, P., & Colau, D. (2005) · European Journal of Immunology · doi:10.1002/eji.200425847 · Cited by 41 · see citing works
Novel immune checkpoint blocker approved for the treatment of advanced melanoma
Galluzzi, L., Kroemer, G., & Eggermont, A. M. M. (2014) · OncoImmunology · doi:10.4161/21624011.2014.967147 · Cited by 36 · see citing works
Abdulrahman, Z., de Miranda, N. F. C. C., van Esch, E. M. G., van Steenwijk, P. J. D. V., Nijman, H. W., Welters, M. J. P., van Poelgeest, M. I. E., & van der Burg, S. H. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000563 · Cited by 36 · see citing works
Histone deacetylases 1 and 2 restrain CD4+ cytotoxic T lymphocyte differentiation
Preglej, T., Hamminger, P., Luu, M., Bulat, T., Andersen, L., Göschl, L., Stolz, V., Rica, R., Sandner, L., Waltenberger, D., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133393 · Cited by 36 · see citing works
Dysregulation of Circulating Follicular Helper T Cells in Nonsmall Cell Lung Cancer
Shi, W., Li, X., Cha, Z., Sun, S., Wang, L., Jiao, S., Yang, B. Y., Shi, Y., Wang, Z., Wu, Z., et al. (2014) · DNA and Cell Biology · doi:10.1089/dna.2013.2332 · Cited by 34 · see citing works
Zhang, Y., Sun, Z., Nicolay, H. J. M., Meyer, R. G., Renkvist, N., Stroobant, V., Corthals, J., Carrasco, J., Eggermont, A. M. M., Marchand, M., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.4.2404 · Cited by 34 · see citing works
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Dillard, P., Köksal, H., Maggadottir, S. M., Winge-Main, A., Pollmann, S., Ménard, M., Myhre, M. R., Mælandsmo, G. M., Flørenes, V. A., Gaudernack, G., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.019 · Cited by 34 · see citing works
Chandra, J., Woo, W.-P., Finlayson, N., Liu, H. Y.-H., McGrath, M. L., Ladwa, R., Brauer, M., Xu, Y., Hanson, S. J., Panizza, B. J., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02720-7 · Cited by 33 · see citing works
McCann, K. J., Mander, A., Cazaly, A. M., Chudley, L., Stasakova, J., Thirdborough, S. M., King, A., Lloyd-Evans, P., Buxton, E., Edwards, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2507 · Cited by 31 · see citing works
Meng, X., Yu, X., Dong, Q., Xu, X., Li, J., Xu, Q., Ma, J., & Changhong, Z. (2018) · Oncology Letters · doi:10.3892/ol.2018.9112 · Cited by 25 · see citing works
Phan-Lai, V., Dang, Y., Gad, E. A., Childs, J. S., & Disis, M. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2273 · Cited by 24 · see citing works
Zaidi, N., Quezada, S. A., Kuroiwa, J. M. Y., Zhang, L., Jaffee, E. M., Steinman, R. M., & Wang, B. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14049 · Cited by 22 · see citing works
Challenges in staining t cells using HLA class ii tetramers
Kwok, W. W. (2003) · Clinical Immunology · doi:10.1016/s1521-6616(02)00018-9 · Cited by 22 · see citing works
Rapid generation of NY-ESO-1-specific CD4+THELPER1 cells for adoptive T-cell therapy
Kayser, S., Boβ, C., Feucht, J., Witte, K.-E., Scheu, A., Bülow, H.-J., Joachim, S., Stevanović, S., Schumm, M., Rittig, S. M., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.1002723 · Cited by 20 · see citing works
T cell subsets and colorectal cancer: Discerning the good from the bad
Scurr, M. J., Gallimore, A., & Godkin, A. J. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.08.004 · Cited by 19 · see citing works
Chen, X., Wang, Y., Wang, J., Wen, J., Jia, X., Wang, X., & Zhang, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.8612 · Cited by 18 · see citing works
Costa-Nunes, C., Cachot, A., Bobisse, S., Arnaud, M., Genolet, R., Baumgaertner, P., Speiser, D. E., Alves, P. M. S., Sandoval, F., Adotévi, O., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1356 · Cited by 17 · see citing works
Self-citationAdvances in Single Cell Technologies in Immunology
Choi, J. R. (2020) · BioTechniques · doi:10.2144/btn-2020-0047 · Cited by 15 · see citing works
Ayyoub, M., Pignon, P., Dojcinovic, D., Raimbaud, I., Old, L. J., Luescher, I. F., & Valmori, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1485 · Cited by 14 · see citing works
Contreras, A., Beems, M. V., Tatar, A. J., Sen, S., Srinand, P., Suresh, M., Luther, T. K., & Cho, C. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0358-2 · Cited by 13 · see citing works
Therapeutic Vaccine for Lymphoma
Lee, S., Neelapu, S. S., & Kwak, L. W. (2007) · Yonsei Medical Journal · doi:10.3349/ymj.2007.48.1.1 · Cited by 11 · see citing works
Rockinger, G. A., Guillaume, P., Cachot, A., Saillard, M., Speiser, D. E., Coukos, G., Harari, A., Romero, P. J., Schmidt, J., & Jandus, C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000435 · Cited by 11 · see citing works
Self-citationTumor resistance to CD8+ T cell-based therapeutic vaccination
Huang, Y., Shah, S., & Qiao, L. (2007) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-007-0029-3 · Cited by 9 · see citing works
Flagged first, then by citations
2 of the 158 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Speiser, D. E., Chijioke, O., Schaeuble, K., & Münz, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00521-2 · Cited by 486 · see citing works
Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade
Budimir, N., Thomas, G. D., Dolina, J. S., & Salek‐Ardakani, S. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0515 · Cited by 302 · see citing works
The Era of Cytotoxic CD4 T Cells
Cenerenti, M., Saillard, M., Romero, P. J., & Jandus, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867189 · Cited by 167 · see citing works
Self-citationHigh-throughput spatiotemporal monitoring of single-cell secretions via plasmonic microwell arrays
Ansaryan, S., Liu, Y., Li, X., Economou, A. M., Eberhardt, C. S., Jandus, C., & Altug, H. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01017-1 · Cited by 89 · see citing works
Self-citationExosomal cargos-mediated metabolic reprogramming in tumor microenvironment
Tan, S., Yang, Y., Yang, W., Han, Y., Huang, L., Yang, R., Hu, Z., Tao, Y., Liu, L., Li, Y., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02634-z · Cited by 79 · see citing works
Yadav, D., Kwak, M., Chauhan, P., Puranik, N., Lee, P. C.-W., & Jin, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.016 · Cited by 58 · see citing works
Adotévi, O., Vernerey, D., Jacoulet, P., Meurisse, A., Laheurte, C., Almotlak, H., Jacquin, M., Kaulek, V., Boullerot, L., Malfroy, M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00096 · Cited by 49 · see citing works
An, Q., Duan, L., Wang, Y., Wang, F., Liu, X., Liu, C., & Hu, Q. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06167-1 · Cited by 23 · see citing works
Baron, M., Drohat, P., Crawford, B., Hornicek, F. J., Best, T. M., & Kouroupis, D. (2023) · Bioengineering · doi:10.3390/bioengineering10101187 · Cited by 19 · see citing works
Tissue adaptation of CD4 T lymphocytes in homeostasis and cancer
Pereira, M. V. A., Galvani, R. G. A., Gonçalves-Silva, T., de Vasconcelos, Z. F. M., & Bonomo, A. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1379376 · Cited by 18 · see citing works
Roles of HMGBs in Prognosis and Immunotherapy: A Pan-Cancer Analysis
Lin, T., Zhang, Y., Lin, Z., & Peng, L. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.764245 · Cited by 18 · see citing works
Hartimath, S. V., Ramasamy, B., Xuan, T. Y., Rong, T. J., Khanapur, S., Cheng, P. K. C., Hwang, Y. Y., Robins, E. G., & Goggi, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010150 · Cited by 13 · see citing works
Pezzana, S., Blaess, S., Traenkle, B., Schaefer, A., Ruoff, L., Tako, B., Vega, S. C., Kaiser, P. D., Wagner, T. R., González-Menéndez, I., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw1924 · Cited by 8 · see citing works
Pezzana, S., Blaess, S., Kortendieck, J., Hemmer, N., Tako, B., Pietura, C., Ruoff, L., Riel, S., Schaller, M., González-Menéndez, I., et al. (2024) · Theranostics · doi:10.7150/thno.95173 · Cited by 7 · see citing works
Sefland, Ø., Gullaksen, S., Omsland, M., Reikvam, H., Galteland, E., Tran, H. T. T., Spetalen, S., Singh, S., van Zeeburg, H. J. T., van de Loosdrecht, A. A., et al. (2024) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.22197 · Cited by 6 · see citing works
Deciphering CD4+ T cell‐mediated responses against cancer
Kirkpatrick, C. A., & Lu, Y. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23730 · Cited by 5 · see citing works
Zhu, Z., Wang, Z., Wu, Q., Miao, D.-L., Jin, Y.-Q., & Chen, L. (2024) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000528 · Cited by 3 · see citing works
Bouzianas, D. G., & Bouziana, S. D. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00186 · Cited by 2 · see citing works
Yan, J., Yang, Y., Lu, J., Yuan, Y., Wu, X., Huang, J., & Zhang, S. (2023) · Iranian Journal of Public Health · doi:10.18502/ijph.v52i11.14042 · Cited by 2 · see citing works
Conventional T Cell Subsets and Their Roles Within the Tumor Microenvironment
Azimnasab-sorkhabi, P., Soltani-asl, M., Ansa-Addo, E. A., & Kfoury, J. R. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_332
Trioën, C. (2024) · doi:10.70675/7c132518z8997z4d01z8084z87c06a661e5a
Cenerenti, M., Garnica, J., Saillard, M., Gueguen, P., Wolf, B., Lemaître, F., Marone, R., Liu, Y., Cornu, A., Dumez, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.13.718113
Self-citationRole of CD4+ T-cells in cancer immunology
Rajput, M. S., Saxena, B., Gupta, R., Mandlik, D., & Natesan, G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41551-7.00011-4
- Authors
- Saillard, M., Cenerenti, M., Romero, P., & Jandus, C.
- Affiliations
- University of Lausanne (CH)
- University of Geneva (CH)
- Corresponding author
- Jandus, Camilla
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2021-05-04
- Volume
- 9
- Issue
- 5
- Pages
- 454
- ISSN
- 2076-393X (ISSN-L)
- PMC
- PMC8147771
- OpenAlex
- W3158325165
- Cited by
- 23
- References
- 158
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 7 · 2023: 6 · 2022: 4 · 2021: 2
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Vaccines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, cc-by)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- IRIS (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD4+ T cells, cancer immunotherapy, immune checkpoint blockade, adoptive cell transfer, cancer vaccination, tumor microenvironment, CD4+ T cell subsets, antitumor immunity, immune monitoring, single-cell analysis, cytokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
